Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.39B P/E - EPS this Y -4.30% Ern Qtrly Grth -
Income -329.12M Forward P/E -3.32 EPS next Y 1.70% 50D Avg Chg -4.00%
Sales 35.33M PEG 0.02 EPS past 5Y - 200D Avg Chg -27.00%
Dividend N/A Price/Book 1.57 EPS next 5Y -97.20% 52W High Chg -65.00%
Recommedations 1.70 Quick Ratio 20.18 Shares Outstanding 132.34M 52W Low Chg 18.00%
Insider Own 3.45% ROA -24.58% Shares Float 94.44M Beta -
Inst Own 98.37% ROE -40.40% Shares Shorted/Prior 10.69M/11.81M Price 11.44
Gross Margin - Profit Margin - Avg. Volume 1,222,646 Target Price 23.05
Oper. Margin -921.31% Earnings Date May 2 Volume 717,987 Change -3.95%
About Relay Therapeutics, Inc.

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Relay Therapeutics, Inc. News
05/02/24 Relay Therapeutics Outperforms Revenue Expectations in Q1 2024
05/02/24 Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Tops Revenue Estimates
05/02/24 Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
04/25/24 Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024
04/11/24 Relay Therapeutics to Participate in Upcoming Investor Conferences
03/17/24 11 Oversold Biotech Stocks To Buy Right Now
03/15/24 3 Precision Medicine Stocks That Could Benefit From the Industry’s Rise
03/13/24 Does Relay Therapeutics, Inc. (RLAY) Have the Potential to Rally 146.52% as Wall Street Analysts Expect?
02/26/24 Relay Therapeutics to Participate in Three Upcoming Investor Conferences
02/26/24 Wall Street Analysts See a 131.6% Upside in Relay Therapeutics, Inc. (RLAY): Can the Stock Really Move This High?
02/24/24 Relay Therapeutics Full Year 2023 Earnings: Beats Expectations
02/22/24 Relay Therapeutics Inc (RLAY) Reports Full Year 2023 Financial Results and Corporate Highlights
02/22/24 Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
02/15/24 Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024
02/15/24 Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?
02/15/24 Relay Therapeutics, Inc. (RLAY) Moves 10.0% Higher: Will This Strength Last?
02/01/24 Relay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
01/18/24 Bank of America Says These 3 Healthcare Stocks Have up to ~160% Upside Potential
01/08/24 Relay Therapeutics Announces $30 Million Private Placement Financing
09:55 AM Xencor (XNCR) Soars 6.0%: Is Further Upside Left in the Stock?
RLAY Chatroom

User Image alan93 Posted - 8 hours ago

$RLAY

User Image alan93 Posted - 9 hours ago

$RLAY where's everybody at?

User Image DonCorleone77 Posted - 1 day ago

$RLAY Relay Therapeutics reports Q1 EPS (62c), consensus (71c) Reports Q1 revenue $10M, consensus $90K. The revenue increase was primarily due to a payment of $10M in connection with a milestone achieved under the company's Collaboration and License Agreement with Genentech during Q1. As of March 31, cash, cash equivalents and investments totaled $749.6M compared to $750.1M as of December 31, 2023. The company expects its current cash, cash equivalents and investments will be sufficient to fund its current operating plan into the second half of 2026.

User Image Stock_Titan Posted - 1 day ago

$RLAY Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights https://www.stocktitan.net/news/RLAY/relay-therapeutics-reports-first-quarter-2024-financial-results-and-bwehnkxjxbkt.html

User Image AivelX Posted - 1 day ago

πŸ’‘ #AivelX After-Hours Earnings Insights (4/5) $POST - Ref.Earnings: 805 Next Day: 46% new high (max 12.1%) vs 54% new low (max -28%) 5 Days Later: 56% new highs, 70% new lows Same Week: 66% broke 103 (-2%) $RLAY - Ref.Earnings: 23 Next Day: 35% new high (max 13%) vs 57% new low (max -19.3%) 5 Days Later: 57% new highs, 78% new lows Same Week: 43% broke 8 (8%) $SAND - Ref.Earnings: 118 Next Day: 70% new high (max 43.7%) vs 13% new low (max -19.2%) 5 Days Later: 77% new highs, 31% new lows Same Week: 26% broke 5 (-8%) $SQ - Ref.Earnings: 15 Next Day: 27% new high (max 3.7%) vs 47% new low (max -10.4%) 5 Days Later: 67% new highs, 67% new lows Same Week: 27% broke 62.3 (-10%) $SWN - Ref.Earnings: 37 Next Day: 24% new high (max 15.9%) vs 62% new low (max -17.4%) 5 Days Later: 35% new highs, 68% new lows Same Week: 8% broke 6.5 (-7%) https://aivelx.com #AivelX #AI #Python

User Image insiderbuyingselling Posted - 04/29/24

$RLAY new insider selling: 1623 shares. http://insiderbuyingselling.com/?t=RLAY

User Image insiderbuyingselling Posted - 04/29/24

$RLAY new insider selling: 1695 shares. http://insiderbuyingselling.com/?t=RLAY

User Image insiderbuyingselling Posted - 04/29/24

$RLAY new insider selling: 2686 shares. http://insiderbuyingselling.com/?t=RLAY

User Image Stock_Titan Posted - 04/25/24

$RLAY Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024 https://www.stocktitan.net/news/RLAY/relay-therapeutics-to-announce-first-quarter-2024-financial-results-305oe4btbir5.html

User Image LabPsycho Posted - 04/25/24

$RLAY Why the non-stop beating?

User Image Stocksrunner Posted - 04/24/24

πŸ“ˆ Today's Top Performers: $CZOO $DJT $WISA $SOL $RLAY! πŸš€ These stocks started low but soared to impressive heights by market close. Keep an eye on their momentum for potential opportunities!

User Image LabPsycho Posted - 04/19/24

$RLAY Nice call and sooner than expected. RLAY $5.95

User Image YouOnlyLiveTwice Posted - 04/18/24

$RLAY 6-12 months BK

User Image LabPsycho Posted - 04/18/24

$RLAY big dump at the open knocking this down to $5.95....I think will retrace and go below that in a few weeks

User Image Stock_Titan Posted - 04/11/24

$RLAY Relay Therapeutics to Participate in Upcoming Investor Conferences https://www.stocktitan.net/news/RLAY/relay-therapeutics-to-participate-in-upcoming-investor-k5aji9g7leds.html

User Image Jajhrbdisn Posted - 04/11/24

$RLAY Galactic Stock Savant is smoking drugs. Relay has by far the best science and backers, and it’s not close. Recursion is an AI hype company, you have been warned $RLAY, $RXRX

User Image MissHollandia Posted - 04/10/24

$SLNA πŸ€žπŸ˜‰β˜β˜β˜ AH movers $RENT $ALPN $VERA $RLAY

User Image Galactic_Stock_Savant Posted - 03/31/24

$RXRX Just remember $RXRX recursion pharmaceuticals remains the most advanced in the field of Artificial intelligence biotech stocks when compared across the sector It’s the only play that does real life wet tests with real medicines in a lab The rest just do simulations on the computer and have no physical backing, no brainer to have a heavy position in rxrx Chart below $RLAY $SDGR $LTRN $NVDA

User Image Galactic_Stock_Savant Posted - 03/31/24

Just remember $RXRX recursion pharmaceuticals remains the most advanced in the field of Artificial intelligence biotech stocks when compared across the sector It’s the only play that does real life wet tests with real medicines in a lab The rest just do simulations on the computer and have no physical backing, no brainer to have a heavy position in rxrx $RLAY $SDGR $LTRN $NVDA

User Image StockInvest_us Posted - 03/30/24

Today $RLAY shows SELL signal (TA) for short term. Technical analysis source: https://stockinvest.us/l/J9hi6wSgMx

User Image Galactic_Stock_Savant Posted - 03/30/24

$RXRX recursion remains the most advanced in the field of Artificial intelligence biotech stocks when compared across the sector $RLAY $SDGR $LTRN $NVDA

User Image insiderbuyingselling Posted - 03/30/24

$RLAY new insider selling: 348 shares. http://insiderbuyingselling.com/?t=RLAY

User Image insiderbuyingselling Posted - 03/30/24

$RLAY new insider selling: 765 shares. http://insiderbuyingselling.com/?t=RLAY

User Image TheLearnerEarner Posted - 03/29/24

$RLAY nice 10%+ compound gains since this trade idea was posted πŸ’Έ FOLLOW for more FREE trade idea alerts πŸ“Ÿ

User Image TheLearnerEarner Posted - 03/27/24

Good morning all πŸŒ„ Why chase a trade when you can be in 1st? 🏧 All stocks posted are HUGELY UNDERVALUED and have a great intrinsic value & analyst PT. Buy LOW Sell HIGH πŸ’² SWING TRADE oversold HOT stock ideas to watch this week: $SINT - $RLAY - $REKR - LUXH - DPRO - AMLX - QNRX - QTI - EVC πŸ’‘ SWING TRADE oversold stocks have a full report posted in my profile with research from various websites πŸ”¬ (the above have good technical attributes after analysing the different timeframes on the chart and could potentially start gaining within 3-8 days) πŸ“‹ (if you do not see a trade idea mentioned on the watch list then it either hit my stop loss and i am trying for a re-entry at a cheaper price, the trades momentum slowed down before gaining anything or i am not currently in the trade) (you must use your own judgement in a swing trade) πŸ”Ž * 3 out of 4 markets are GREEN 🟩 * 1 out of 4 markets are RED πŸŸ₯ (market info accurate at time of posting) βœ”οΈ

User Image TheLearnerEarner Posted - 03/26/24

$RLAY added QUALITY FAIR VALUE stock swing trade - healthcare - small cap - 14x analysts coverage - 6x analysts buy rating - 3.5x relative volume - revenue is forecast to grow 43.78% per year - trading at 96.3% below estimate of its fair value - short to long term gains πŸ’Ž Rsi: 33.42 (oversold upwards momentum) πŸ“Š Analyst Price Target: $23.05 - $34.65 (206.11% - 359.55% above Price) 🌟 Range (12m) $5.95 - $19.23 πŸ’° NEWSDESK (article idea is for RLAY only) πŸ“° https://investorplace.com/2024/03/3-precision-medicine-stocks-that-could-benefit-from-the-industrys-rise/

User Image LabPsycho Posted - 03/12/24

$KRON $RLAY Still holding true months later

User Image Hpad06 Posted - 03/12/24

$RLAY any reason for the drop?

User Image groots Posted - 03/11/24

$RLAY I cared $1 once, does that make your little itty-bitty heart fill better little emotional pipsqueak πŸ˜†

User Image jltransport Posted - 03/06/24

$RLAY sheesh, does anyone even care about this stock?

Analyst Ratings
Stifel Buy Feb 22, 24
HC Wainwright & Co. Buy Dec 11, 23
HC Wainwright & Co. Buy Nov 8, 23
HC Wainwright & Co. Buy Oct 17, 23
HC Wainwright & Co. Buy Aug 17, 23
Oppenheimer Outperform Aug 9, 23
HC Wainwright & Co. Buy Jun 9, 23
JMP Securities Market Outperform May 5, 23
Jefferies Hold Apr 20, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Rahmer Peter See remarks See remarks Jan 29 Sell 9.64 1,651 15,916 514,977 01/31/24
Catinazzo Thomas Chief Financial Offi.. Chief Financial Officer Jan 29 Sell 9.64 2,005 19,328 341,846 01/31/24
Bergstrom Donald A President, R&D President, R&D Jan 29 Sell 9.64 3,178 30,636 530,878 01/31/24
Rahmer Peter See remarks See remarks Dec 27 Sell 11.51 244 2,808 316,628 12/29/23
Bergstrom Donald A President, R&D President, R&D Oct 30 Sell 6.03 3,451 20,810 235,033 11/01/23
Adams Brian Chief Legal Officer Chief Legal Officer Oct 30 Sell 6.03 1,632 9,841 129,961 11/01/23
Bergstrom Donald A President, R&D President, R&D Sep 27 Sell 8.38 648 5,430 238,484 09/29/23
Rahmer Peter See remarks See remarks Sep 27 Sell 8.38 244 2,045 318,226 09/29/23
Catinazzo Thomas Chief Financial Offi.. Chief Financial Officer Sep 27 Sell 8.38 294 2,464 145,842 09/29/23
Rahmer Peter See remarks See remarks Jul 28 Sell 11.80 1,352 15,954 316,808 07/31/23
Catinazzo Thomas Chief Financial Offi.. Chief Financial Officer Jul 28 Sell 11.80 1,693 19,977 146,136 07/31/23
Rahmer Peter See remarks See remarks Apr 28 Sell 11.16 1,657 18,492 156,586 06/01/23
Catinazzo Thomas Chief Financial Offi.. Chief Financial Officer Apr 28 Sell 11.16 863 9,631 149,272 05/01/23
Rahmer Peter See remarks See remarks Mar 27 Sell 15.36 297 4,562 158,243 03/28/23
Catinazzo Thomas Chief Financial Offi.. Chief Financial Officer Mar 27 Sell 15.36 347 5,330 150,135 03/28/23
Bergstrom Donald A President, R&D President, R&D Mar 27 Sell 15.36 763 11,720 244,084 03/28/23
Adams Brian Chief Legal Officer Chief Legal Officer Mar 27 Sell 15.36 347 5,330 135,745 03/28/23
Patel Sanjiv President and CEO President and CEO Jan 17 Sell 20.37 84,000 1,711,080 254,554 01/19/23
Patel Sanjiv President and CEO President and CEO Jan 17 Option 5.04 84,000 423,360 282,554 01/19/23
Catinazzo Thomas Chief Financial Offi.. Chief Financial Officer Dec 27 Sell 14.49 445 6,448 50,231 12/28/22
Porter Andy Chief Administrative.. Chief Administrative Officer Sep 27 Sell 22.73 259 5,887 45,612 09/29/22
Catinazzo Thomas Chief Financial Offi.. Chief Financial Officer Sep 27 Sell 22.73 443 10,069 51,775 09/29/22
Bergstrom Donald A President, R&D President, R&D Sep 27 Sell 22.73 976 22,184 88,683 09/29/22
Adams Brian Chief Legal Officer Chief Legal Officer Sep 27 Sell 22.73 294 6,683 62,548 09/29/22
Patel Sanjiv President and CEO President and CEO Sep 13 Sell 24.24 42,000 1,018,080 254,554 09/15/22
Patel Sanjiv President and CEO President and CEO Sep 13 Option 4.12 42,000 173,040 268,554 09/15/22
Murcko Mark Director Director Sep 08 Sell 29.95 25,000 748,750 996,952 09/08/22
Catinazzo Thomas Chief Financial Offi.. Chief Financial Officer Sep 08 Option 4.12 26,257 108,179 78,475 09/08/22
Catinazzo Thomas Chief Financial Offi.. Chief Financial Officer Sep 08 Sell 30 26,257 787,710 52,218 09/08/22
Bergstrom Donald A President, R&D President, R&D Sep 08 Option 4.12 25,000 103,000 114,659 09/08/22
Bergstrom Donald A President, R&D President, R&D Sep 08 Sell 30 25,000 750,000 89,659 09/08/22
Bergstrom Donald A President, R&D President, R&D Sep 02 Option 4.12 4,900 20,188 94,559 09/02/22
Bergstrom Donald A President, R&D President, R&D Sep 02 Sell 25.46 4,900 124,754 89,659 09/02/22
Bergstrom Donald A President, R&D President, R&D Sep 01 Option 4.12 8,100 33,372 97,759 09/01/22
Bergstrom Donald A President, R&D President, R&D Sep 01 Sell 23.07 8,100 186,867 89,659 09/01/22
Bergstrom Donald A President, R&D President, R&D Aug 24 Option 4.12 15,000 61,800 104,659 08/25/22
Bergstrom Donald A President, R&D President, R&D Aug 24 Sell 25 15,000 375,000 89,659 08/25/22
Bergstrom Donald A President, R&D President, R&D Aug 05 Option 4.12 8,000 32,960 97,659 08/08/22
Bergstrom Donald A President, R&D President, R&D Aug 05 Sell 20 8,000 160,000 89,659 08/08/22
Porter Andy Chief Administrative.. Chief Administrative Officer Jul 28 Sell 21.27 452 9,614 45,871 07/29/22
Catinazzo Thomas Chief Financial Offi.. Chief Financial Officer Jul 28 Sell 21.26 734 15,605 52,218 07/29/22
Bergstrom Donald A President, R&D President, R&D Jul 28 Sell 21.27 1,835 39,030 89,659 07/29/22
Bergstrom Donald A President, R&D President, R&D Jul 06 Option 4.12 8,000 32,960 99,494 07/08/22
Bergstrom Donald A President, R&D President, R&D Jul 06 Sell 20 8,000 160,000 91,494 07/08/22
Porter Andy Chief Administrative.. Chief Administrative Officer Jun 27 Sell 20.31 265 5,382 46,323 06/28/22
Catinazzo Thomas Chief Financial Offi.. Chief Financial Officer Jun 27 Sell 20.31 300 6,093 52,952 06/28/22
Adams Brian Chief Legal Officer Chief Legal Officer Jun 27 Sell 20.31 300 6,093 63,576 06/28/22
Bergstrom Donald A President, R&D President, R&D Jun 24 Option 4.12 8,000 32,960 100,493 06/28/22
Bergstrom Donald A President, R&D President, R&D Jun 24 Sell 20.16 8,999 181,420 91,494 06/28/22
Bergstrom Donald A President, R&D President, R&D Apr 28 Option 4.12 13,000 53,560 105,493 05/02/22